Le Lézard

Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue

Twist Bioscience Corporation , a mid-cap growth and value biotech company, today announced preliminary, unaudited revenue for the first quarter of fiscal 2026 ended December 31, 2025. Visit the Events ...
Le Lézard

Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

Harmony Biosciences Holdings, Inc. today announced strong preliminary, unaudited net product revenue for Q4 and full year ...

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations -- Dosing of the first participant in the Phase 1b ...

Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology

Jazz Pharmaceuticals plc looks very undervalued at 2.4x sales as oncology catalysts (Ziihera, Zepzelca, Epidiolex) drive ...